Summit Therapeutics is trading at $13.07 (+4.14%) as the stock stages a sharp recovery from a volatile two-day decline and a close of $12.55 on July 28.
- The move appears to be driven by a broad market rebound following recent biotech sector weakness and geopolitical-driven volatility, as no company-specific catalysts were reported for the session.
- Investor attention remains centered on ivonescimab development spending and PDUFA risks, which continue to serve as the primary background factors for the stock's recent price action.